Breakthrough bioresorbable 3D-printed bone scaffolds with global partner-led growth—held back by a dilutive capital structure and a weak share-price tape.
Overview
Osteopore (OSX.AX) is a Singapore-headquartered, ASX-listed medtech commercializing 3D-printed, bioresorbable PCL bone scaffolds that act as temporary frameworks for bone regeneration and then dissolve over 18–24 months—aiming to eliminate the need for permanent hardware or secondary removal surgeries. Revenue comes from selling off-the-shelf implants (e.g., Osteoplug, Osteomesh) and patient-specific implants designed from CT scans, across craniofacial, orthopaedic, dental/OMF, and aesthetic applications, supported by distribution in 25+ countries. Strategic partnerships—especially an exclusive Zimmer Biomet distribution agreement for craniofacial in EMEA/APAC—are central to scaling. In early 2026, Osteopore expanded into a 3D printing services line (models and surgical guides) to access the broader healthcare 3D printing market. Financially, 2025 revenue rose to ~AUD 3.06m, but ongoing cash burn and reliance on a AUD 20m convertible note facility create significant dilution and investor risk.